Compare Novavax Inc (NVAX) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs ProShares UltraPro Short QQQ ETF — how do they compare? Novavax Inc trades at $12.74 (market cap $1.82B), while ProShares UltraPro Short QQQ ETF trades at $33.02 (market cap $2.23B). The key difference: ProShares UltraPro Short QQQ ETF is the larger of the two by market cap, and Novavax Inc is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and ProShares UltraPro Short QQQ ETF for 12 Days on average.
| NVAX | SQQQ | |
|---|---|---|
Market Cap | $1.82B | $2.23B |
Volume | 6,198,505 | 60,436,012 |
Sector | Health | Leveraged / Inverse |
52-Week High | $12.56 | $89.43 |
52-Week Low | $6.22 | $31.83 |
Typical Hold Time | 59 Days | 12 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
SQQQ (ProShares UltraPro Short QQQ) trades at $33.20, up 3.49% today, reflecting bearish market sentiment toward the Nasdaq 100. Technical indicators show a predominantly bearish signal with moving averages heavily weighted toward selling pressure. The ETF is designed to deliver triple the inverse daily performance of the Nasdaq 100, making it a tactical tool for hedging or speculating on tech sector declines.
SQQQ's outlook remains tied to Nasdaq 100 volatility, with potential gains during market downturns but significant decay risk in flat or rising markets. Investors should consider the high-risk, leveraged nature of this instrument and its suitability primarily for short-term hedging strategies rather than long-term holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
